Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear

Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a wider-ranging pact with China’s Haisco Ph...